{
    "clinical_study": {
        "@rank": "57204", 
        "arm_group": {
            "arm_group_label": "Prednisone versus placebo", 
            "arm_group_type": "Experimental", 
            "description": "Prednisone 2mg/kg orally once a day x 7 days, 1 mg/kg orally once a day x 7 days and then 0.5 mg/kg orally once a day x 7 days"
        }, 
        "brief_summary": {
            "textblock": "This is a double-blind randomized controlled trial assessing the efficacy of adjuvant\n      corticosteroids in clinically diagnosed Pneumocystis jiroveci pneumonia in infants."
        }, 
        "brief_title": "Pneumocystis Jerovici Pneumonia in Infants and Steroids", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Pneumonia, Pneumocystis Jerovici", 
        "condition_browse": {
            "mesh_term": [
                "Pneumonia", 
                "Pneumonia, Pneumocystis"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study aims to determine whether the early administration of adjuvant corticosteroids in\n      addition to high dose oral Co-trimoxazole reduces mortality amongst infants aged 2-6 months\n      with vertically acquired HIV and clinically diagnosed Pneumocystis jiroveci pneumonia.\n      Infants will be randomized to receive either a steroid regime of oral prednisolone at 2\n      mg/kg for 7 days, then 1 mg/kg for 7 days, then 0.5mg/kg for 7 days for a total of 21 days\n      or placebo."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Consecutive infants with HIV and clinical features of Pneumocystis jiroveci pneumonia\n             who require oxygen (oxygen saturations in air < 90%).\n\n          -  Clinical diagnosis of Pneumocystis jiroveci pneumonia will be made by one of the\n             study investigators. All infants must be HIV ELISA positive or exposed, have an\n             oxygen requirement (saturations on air < 90%) and have severe respiratory distress\n             and cough. They may also have a low grade fever, clear chest or diffuse signs on\n             auscultation and features suggestive of Pneumocystis jiroveci infection on chest\n             radiography.\n\n        Exclusion Criteria:\n\n          -  Previous known allergy or hypersensitivity or other contraindication to\n             corticosteroids or co-trimoxazole.\n\n          -  Previous treatment for suspected Pneumocystis jiroveci pneumonia or a delay starting\n             steroids for greater than 24 hours after starting high dose co-trimoxazole.\n\n          -  Patients who are not exposed to HIV.\n\n          -  Infants with known preexisting active pulmonary or cardiac disease.\n\n          -  Patients who do not live within the Blantyre district and who are unable to attend\n             follow up at QECH.\n\n          -  Infants whose parents or guardians refuse consent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "6 Months", 
            "minimum_age": "2 Months"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 9, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02149433", 
            "org_study_id": "Pneumocystis and Steroids"
        }, 
        "intervention": [
            {
                "arm_group_label": "Prednisone versus placebo", 
                "description": "The steroid regime will be oral prednisolone at 2 mg/kg for 7 days, then 1 mg/kg for 7 days, then 0.5mg/kg for 7 days for a total of 21 days.", 
                "intervention_name": "Prednisone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Prednisone versus placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Prednisone"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Pneumocystis Jiroveci", 
            "Steroids", 
            "Infants"
        ], 
        "lastchanged_date": "May 28, 2014", 
        "location": {
            "contact": {
                "email": "lauraanewberry@gmail.com", 
                "last_name": "Laura Newberry, MD", 
                "phone": "265995929733"
            }, 
            "facility": {
                "address": {
                    "city": "Blantyre", 
                    "country": "Malawi"
                }, 
                "name": "Queen Elizabeth Central Hospital"
            }, 
            "investigator": {
                "last_name": "Laura Newberry, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Malawi"
        }, 
        "number_of_arms": "1", 
        "official_title": "Early Steroid Use in Infants With Clinical Pneumocystis Jiroveci Pneumonia (PCP) in the Queen Elizabeth Central Hospital, Blantyre, Malawi", 
        "overall_contact": {
            "email": "lauraanewberry@gmail.com", 
            "last_name": "Laura Newberry, MD", 
            "phone": "265995929733"
        }, 
        "overall_contact_backup": {
            "email": "emmolyneux@gmail.com", 
            "last_name": "Elizabeth Molyneux, FRCPCH", 
            "phone": "265995929733"
        }, 
        "overall_official": [
            {
                "affiliation": "Paediatric Department, College of Medicine, University of Malawi", 
                "last_name": "Laura Newberry, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Paediatric Department, College of Medicine, University of Malawi", 
                "last_name": "Elizabeth Molyneux, FRCPCH", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Malawi: College of Medicine Research and Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine whether the addition of oral Prednisolone to standard treatment reduces inpatient mortality by 20% in patients aged 2-6 months with clinical PJP pneumonia.", 
            "measure": "Reduction in inpatient mortality by 20%.", 
            "safety_issue": "No", 
            "time_frame": "36 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02149433"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Malawi College of Medicine", 
            "investigator_full_name": "Elizabeth Molyneux", 
            "investigator_title": "Lecturer Paediatrics and Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "To determine whether steroids significantly increase the number of patients that successfully commence anti-retroviral treatment.", 
                "measure": "Commencement of antiretroviral treatment", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }, 
            {
                "description": "To determine whether steroids significantly increase the number of patients that survive to 6 months following commencement of anti-retrovirals.", 
                "measure": "6 month survival", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }, 
            {
                "description": "To determine whether steroids significantly alter morbidity as determined by number of days spent in hospital as an inpatient and number of days on oxygen.", 
                "measure": "Morbidity (days in hospital and days on oxygen)", 
                "safety_issue": "No", 
                "time_frame": "36 months"
            }
        ], 
        "source": "University of Malawi College of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Malawi College of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}